| Year |
Citation |
Score |
| 2019 |
Jolly MK, Ware KE, Xu S, Gilja S, Shetler S, Yang Y, Wang X, Austin RG, Runyambo D, Hish AJ, Bartholf DeWitt S, George JT, Kreulen RT, Boss MK, Lazarides AL, et al. E-cadherin represses anchorage-independent growth in sarcomas through both signaling and mechanical mechanisms. Molecular Cancer Research : McR. PMID 30862685 DOI: 10.1158/1541-7786.Mcr-18-0763 |
0.308 |
|
| 2019 |
Xu S, Ware KE, Ding Y, Kim SY, Sheth MU, Rao S, Chan W, Armstrong AJ, Eward WC, Jolly MK, Somarelli JA. An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance. Journal of Clinical Medicine. 8. PMID 30736412 DOI: 10.3390/Jcm8020205 |
0.32 |
|
| 2017 |
Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar S, Glogowska MJ, Smith MA, Kako SL, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, et al. EGFR mediates responses to small molecule drugs targeting oncogenic fusion kinases. Cancer Research. PMID 28428274 DOI: 10.1158/0008-5472.Can-17-0109 |
0.729 |
|
| 2014 |
Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3299-309. PMID 24771645 DOI: 10.1158/1078-0432.CCR-13-3060 |
0.66 |
|
| 2013 |
Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2: e39. PMID 23552882 DOI: 10.1038/oncsis.2013.4 |
0.535 |
|
| 2011 |
Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5016-25. PMID 21673064 DOI: 10.1158/1078-0432.Ccr-11-0050 |
0.65 |
|
| 2010 |
Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. Plos One. 5: e14117. PMID 21152424 DOI: 10.1371/Journal.Pone.0014117 |
0.774 |
|
| 2010 |
Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Molecular Cancer Therapeutics. 9: 1298-307. PMID 20423999 DOI: 10.1158/1535-7163.Mct-09-0707 |
0.435 |
|
| 2009 |
Kono SA, Marshall ME, Ware KE, Heasley LE. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 95-102. PMID 19501013 DOI: 10.1016/J.Drup.2009.05.001 |
0.759 |
|
| 2009 |
Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Heasley LE. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Molecular Pharmacology. 75: 196-207. PMID 18849352 DOI: 10.1124/Mol.108.049544 |
0.786 |
|
| Show low-probability matches. |